Aug292019UncategorizedCategory: UncategorizedBy Charlotte Maddalena29 August 2019 Author: Charlotte Maddalena Post navigationPreviousPrevious post:Alizé Pharma 3NextNext post:ORPHELIA announces Orphan Drug Designation for Kimozo®Related PostsSIOP 2022, Barcelona, Spain: September 28-October 1, 202223 September 2022Organisation Inter Régionale Hémato-Onco pédiatrique14 September 2022Five new projects supported by our Foundation5 July 2022First patient included under the French Early Access Program granted to ORPHELIA Pharma for KIMOZO®22 June 2022ORPHELIA Pharma and Gustave Roussy announce the publication of the scientific work related to the first temozolomide oral suspension9 June 2022Progress of OREGA Biotech’s CD39 program: IPH5201 to advance into Phase 2 clinical trial in lung cancer7 June 2022
First patient included under the French Early Access Program granted to ORPHELIA Pharma for KIMOZO®22 June 2022
ORPHELIA Pharma and Gustave Roussy announce the publication of the scientific work related to the first temozolomide oral suspension9 June 2022
Progress of OREGA Biotech’s CD39 program: IPH5201 to advance into Phase 2 clinical trial in lung cancer7 June 2022
